NIDDK Central Repository - Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.

An official website of the United States government

NIDDK Central Repository

Publication Information

DOI

10.1016/j.jhep.2014.08.013

PubMed ID

25135867

Public Release Type

Journal

Publication Year

2015

Affiliation

Liver Center, Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rtchung@partners.org.

Authors

Chung RT, King LY, Simon TG, Zheng H

Studies

HALT-C

Citation

Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol 2015 Jan;62(1):18-23. Epub 2014 Aug 15.

Abstract

Therapies that slow fibrosis progression in chronic liver disease are needed. Animal models have demonstrated that statins prevent the progression of hepatic fibrosis, but human data is lacking so far. We evaluated the association between statins and fibrosis progression in the HALT-C trial cohort.